Cargando…
Low-dose rituximab should be used for treating MS in resource-limited settings: Yes
Autores principales: | Piehl, Fredrik, Mathew, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131395/ https://www.ncbi.nlm.nih.gov/pubmed/35437089 http://dx.doi.org/10.1177/13524585221089890 |
Ejemplares similares
-
Low-dose rituximab should be used for treating MS in resource-limited
settings: No
por: Mateen, Farrah J
Publicado: (2022) -
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended
interval dosing—“Yes”
por: Rolfes, Leoni, et al.
Publicado: (2021) -
Much, if not all, of the cortical damage in MS can be attributed to the microglial cell – Yes
por: van Wageningen, Thecla A, et al.
Publicado: (2018) -
Serum MOG IgG titres should be performed routinely in the diagnosis and follow-up of MOGAD: Yes
por: Reindl, Markus, et al.
Publicado: (2023) -
Presymptomatic MS or radiologically isolated syndrome (RIS) should be actively monitored and treated – NO
por: Smets, Ide
Publicado: (2023)